Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.717
https://www.valueinhealthjournal.com/article/S1098-3015(14)02647-3/fulltext
Title :
Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02647-3&doi=10.1016/j.jval.2014.08.717
First page :
A348
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
139